会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Purification of coenzyme A
    • 辅酶A的纯化
    • US3935072A
    • 1976-01-27
    • US384212
    • 1973-07-31
    • Ichiro ChibataTetsuya TosaYuhsi Matuo
    • Ichiro ChibataTetsuya TosaYuhsi Matuo
    • C12P19/32C07G7/02C07G3/00C07G7/00
    • C12P19/32Y10S530/825
    • Coenzyme A is purified by a process involving contacting a cyanogen halide-activated water-insoluble polysaccharide with a cell-free extract of a coenzyme A-producing microorganism to immobilize proteins such as enzymes having affinity for coenzyme A on the polysaccharide. The immobilized proteins are then contacted with a coenzyme A-containing solution to absorb coenzyme A followed by eluting coenzyme A from the immobilized proteins. Alternatively, the proteins having affinity for coenzyme A may be isolated from the cell-free extract prior to immobilization by absorbing the proteins on coenzyme A immobilized on a cyanogen halide-activated water-insoluble polysaccharide followed by eluting the proteins from the immobilized coenzyme A.
    • 辅酶A通过使卤化氰活化的水不溶性多糖与产生辅酶A的微生物的无细胞提取物接触的方法进行纯化,从而将对辅酶A具有亲和性的酶等蛋白质固定在多糖上。 然后将固定的蛋白质与含辅酶A的溶液接触以吸收辅酶A,然后从固定化蛋白质洗脱辅酶A. 或者,可以通过将固定在氰卤化物活化的水不溶性多糖上的辅酶A上的蛋白质吸收固定化,然后从固定化的辅酶A洗脱蛋白质,在固定前从无细胞提取物中分离出对辅酶A具有亲和力的蛋白质。
    • 6. 发明授权
    • Blood purification means
    • 血液净化手段
    • US3963613A
    • 1976-06-15
    • US536641
    • 1974-12-26
    • Ichiro ChibataTetsuya TosaTakao Mori
    • Ichiro ChibataTetsuya TosaTakao Mori
    • A61F2/02A61M1/16A61M1/36B01D31/00
    • A61F2/022A61M1/1696A61M1/3687
    • A blood purification means whereby blood of a patient to be treated is led around an external circuit connecting to the patient's blood stream and is brought into direct or indirect contact with a fumarate solution, and is further brought into direct or indirect contact with an enzymic preparation, which is suitably an aspartase preparation, which catalyzes a reaction of L-aspartic acid formation from fumaric acid and ammonia. The purification means may further include a preliminary stage or stages whereat an unrequired substance in a patient's blood is decomposed to a non toxic substance and ammonia subsequently convertable to aspartic acid, and may also include a low molecular sieve means preventing re-entry of aspartic acid produced into the patient's blood stream.
    • 一种血液净化装置,其特征在于,将待治疗的患者的血液引导到连接患者血液流的外部回路,并与富马酸盐溶液直接或间接接触,并进一步与酶制剂直接或间接接触 其合适地是天冬氨酰胺酶制剂,其催化由富马酸和氨形成的L-天冬氨酸的反应。 净化装置还可以包括预备阶段或阶段,其中将患者血液中的不需要物质分解成无毒物质,然后氨转化成天冬氨酸,还可以包括防止天冬氨酸再次进入的低分子筛 产生到患者的血液中。